We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-22.52%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.18B
AUM Growth
-$1.05B
Cap. Flow
-$488M
Cap. Flow %
-41.25%
Top 10 Hldgs %
68.01%
Holding
52
New
5
Increased
2
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$23.5M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.77M
3
ABCL icon
AbCellera Biologics
ABCL
+$6.35M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.79M
5
RLAY icon
Relay Therapeutics
RLAY
+$4.53M

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$72.7M
2
NVTA
Invitae Corporation
NVTA
+$49.4M
3
EXAS
Exact Sciences
EXAS
+$47.1M
4
CDNA icon
CareDx
CDNA
+$42.7M
5
FATE icon
Fate Therapeutics
FATE
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTK
51
DELISTED
DermTech, Inc. Common Stock
DMTK
– –
-1,745,000
Closed -$25.6M
DBTX
52
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
– –
-330,000
Closed -$1M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Casdin Capital held 52 positions worth $1.18B, down 47% from $2.23B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Casdin Capital withdrew a net $488M in Q2 2022, closing 12 positions and reducing 19 holdings. Its most notable exit was Pacific Biosciences, an estimated $72.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Karuna Therapeutics, Inc. Common Stock worth $10.8M.

  • Casdin Capital's largest Q2 2022 buy was Karuna Therapeutics, Inc. Common Stock: 85,000 shares worth $10.8M.
  • Casdin Capital added most to GeneDx Holdings in Q2 2022, an estimated $23.5M increase.
  • Casdin Capital's biggest Q2 2022 reduction was Invitae Corporation, cutting an estimated $49.4M.
  • Casdin Capital fully exited Pacific Biosciences in Q2 2022, selling an estimated $72.7M.
  • Casdin Capital's ten largest holdings make up 68% of its $1.18B portfolio in Q2 2022.
  • Casdin Capital opened 5 new positions and closed 12 in Q2 2022.
  • Casdin Capital's portfolio value fell 47% quarter-over-quarter to $1.18B.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.